Claire N Harrison Selected Research

ruxolitinib

1/2022	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
1/2022	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
1/2022	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
7/2021	Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center.
5/2021	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
11/2020	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
6/2020	Management of myelofibrosis after ruxolitinib failure.
3/2020	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
2/2020	Current and future role of fedratinib in the treatment of myelofibrosis.
1/2020	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claire N Harrison Research Topics

Disease

51	Primary Myelofibrosis (Myelosclerosis) 07/2022 - 07/2005
23	Neoplasms (Cancer) 01/2022 - 07/2011
17	Polycythemia Vera 12/2022 - 02/2007
13	Essential Thrombocythemia 12/2022 - 07/2005
13	Splenomegaly 06/2020 - 01/2013
11	Thrombocytopenia (Thrombopenia) 01/2022 - 12/2013
9	Hemorrhage 01/2022 - 07/2005
9	Anemia 12/2017 - 01/2013
8	Thrombosis (Thrombus) 10/2020 - 07/2005
5	Cytopenia 01/2022 - 12/2013
4	Disease Progression 01/2022 - 05/2017
4	Thrombocytosis (Thrombocythemia) 01/2021 - 10/2005
4	Fatigue 01/2017 - 07/2011
4	Polycythemia (Erythrocytosis) 11/2009 - 12/2005
3	Infections 10/2017 - 01/2015
2	Venous Thromboembolism 01/2020 - 07/2005
2	Sepsis (Septicemia) 02/2018 - 05/2017
2	Leukemia 01/2018 - 10/2005
2	Systemic Mastocytosis 01/2018 - 01/2017
2	Fever (Fevers) 05/2017 - 07/2013
2	Iron Deficiencies 01/2017 - 01/2012
2	Pruritus (Itching) 08/2016 - 07/2013
2	Pain (Aches) 02/2016 - 07/2013
2	Fibrosis (Cirrhosis) 12/2013 - 06/2009
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 11/2008 - 10/2005
1	Human Influenza (Influenza) 01/2021
1	Adenocarcinoma 03/2020
1	Embolism (Embolus) 12/2018
1	Ischemia 12/2018
1	Hypertension (High Blood Pressure) 12/2018
1	Respiratory Insufficiency (Respiratory Failure) 02/2018
1	Adenocarcinoma of Lung 02/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 02/2018
1	Abdominal Pain (Pain, Abdominal) 02/2018
1	Heart Arrest (Cardiac Arrest) 02/2018
1	Mastocytosis 01/2018
1	Philadelphia Chromosome 01/2018
1	Leukopenia 12/2017
1	Frailty 10/2017
1	Wernicke Encephalopathy (Wernicke's Encephalopathy) 07/2017
1	Heart Failure 05/2017
1	Pneumonia (Pneumonitis) 05/2017
1	Hypotension (Low Blood Pressure) 05/2017
1	Leukocytosis (Pleocytosis) 01/2017
1	Headache (Headaches) 01/2017
1	Dizziness (Lightheadedness) 01/2017
1	Chronic Neutrophilic Leukemia 01/2017
1	Intracranial Sinus Thrombosis (Sinus Thrombosis) 01/2017
1	Herpes Zoster 01/2015
1	Blast Crisis (Blast Phase) 12/2014
1	Weight Loss (Weight Reduction) 07/2013

Drug/Important Bio-Agent (IBA)

37	ruxolitinibIBA 01/2022 - 07/2013
18	Janus Kinase InhibitorsIBA 07/2022 - 01/2013
9	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2022 - 07/2005
9	Janus KinasesIBA 01/2022 - 02/2007
8	fedratinibIBA 01/2022 - 07/2017
6	Syntex adjuvant formulationIBA 12/2017 - 07/2011
5	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2022 - 01/2015
5	Janus Kinase 2IBA 05/2021 - 07/2005
5	Pharmaceutical PreparationsIBA 06/2020 - 01/2017
4	anagrelide (Agrylin)FDA LinkGeneric 01/2018 - 07/2005
3	InterferonsIBA 12/2022 - 03/2016
3	CytokinesIBA 01/2022 - 11/2008
3	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 06/2020 - 02/2018
3	Biological ProductsIBA 10/2018 - 12/2005
3	IronIBA 01/2017 - 01/2012
3	Erythropoietin FDA Link 11/2009 - 02/2007
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 10/2018
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2018 - 07/2005
2	Janus Kinase 1IBA 02/2018 - 01/2016
2	HematinicsIBA 01/2015 - 01/2013
1	imetelstatIBA 07/2022
1	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2022
1	navitoclaxIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Interleukin-1 Receptor-Associated KinasesIBA 01/2022
1	mRNA VaccinesIBA 12/2021
1	BNT162 VaccineIBA 12/2021
1	VaccinesIBA 01/2021
1	Epidermal Growth Factor (EGF)IBA 06/2020
1	Biomarkers (Surrogate Marker)IBA 06/2020
1	AnticoagulantsIBA 01/2020
1	Vitamin K FDA Link 01/2020
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	midostaurinIBA 01/2018
1	CalreticulinIBA 01/2018
1	Immunologic Factors (Immunomodulators)IBA 06/2016
1	SteroidsIBA 06/2016
1	Histamine Antagonists (Antihistamines)IBA 02/2016
1	Antidepressive Agents (Antidepressants)IBA 02/2016
1	Azacitidine (5 Azacytidine)FDA Link 12/2014
1	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2014
1	Phosphotransferases (Kinase)IBA 12/2013

Therapy/Procedure

39	Therapeutics 12/2022 - 06/2009
3	Erythrocyte Transfusion 02/2018 - 01/2017
2	Stem Cell Transplantation 01/2019 - 05/2012
1	Transplantation 01/2019
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Drug Tapering 02/2018
1	Orthopedic Procedures 01/2017